CordenPharma is investing €10 Million in a new line at its Plankstadt, Germany site.
CordenPharma, a contract development and manufacturing organization (CDMO) for APIs, drug products, and packaging, will invest €10 million (almost $12 million) in a new manufacturing line dedicated to producing veterinary drug products for 500-kg scale batch sizes. This new line is part of a production plant that is dedicated to veterinary drug products.
The expansion of the production capabilities at CordenPharma Plankstadt (Germany) is the result of a new, long-term custom manufacturing agreement for an animal health applications. Work began in the second quarter of 2017, with a targeted mechanical completion by the 2nd quarter of 2018 and commercial supply for the global launch campaign is expected to start in the second half of 2018.
The new production line will allow the fully contained handling of highly potent APIs in a dedicated facility for the manufacturing of veterinary drug products, said Frank Hähner, managing director of CordenPharma Plankstadt, in a press release.
This investment in CordenPharma Plankstadt is the latest of several expansions that the company has made in 2017, including other projects in Plankstadt, as well as new projects in Colorado.
Source: CordenPharma
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.